Abbott spins off biopharmaceutical business

Abbott Laboratories has finalized the spinoff of its branded biopharmaceutical business into a publicly traded entity named AbbVie. The new firm will focus on developing a broad portfolio anchored by the blockbuster drug Humira, and it will start with more than 20 mid- to late-stage clinical programs in its pipeline. "AbbVie launches with an outstanding portfolio, a solid pipeline and enthusiastic people who will serve patients and deliver growth," AbbVie Chairman and CEO Richard A. Gonzalez said.

View Full Article in:

Genetic Engineering & Biotechnology News · GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations